WO2001097749A3 - The use of synthetic, non-hormonal 21-aminosteroids and thereof - Google Patents

The use of synthetic, non-hormonal 21-aminosteroids and thereof Download PDF

Info

Publication number
WO2001097749A3
WO2001097749A3 PCT/IB2001/001101 IB0101101W WO0197749A3 WO 2001097749 A3 WO2001097749 A3 WO 2001097749A3 IB 0101101 W IB0101101 W IB 0101101W WO 0197749 A3 WO0197749 A3 WO 0197749A3
Authority
WO
WIPO (PCT)
Prior art keywords
aminosteroids
hormonal
synthetic
hepatitis
prophylaxis
Prior art date
Application number
PCT/IB2001/001101
Other languages
French (fr)
Other versions
WO2001097749A2 (en
Inventor
Patrick Thomas Prendergast
Original Assignee
Kotze Gavin Salomon
Patrick Thomas Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kotze Gavin Salomon, Patrick Thomas Prendergast filed Critical Kotze Gavin Salomon
Priority to AU74383/01A priority Critical patent/AU7438301A/en
Publication of WO2001097749A2 publication Critical patent/WO2001097749A2/en
Publication of WO2001097749A3 publication Critical patent/WO2001097749A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention discloses the use of synthetic, non-hormonal 21-aminosteroids, derivatives, metabolites and precursors thereof in the treatment of viruses, particularly hepatitis and the retroviral infection by HIV. Synthetic non-hormonal 21-aminosteroids are disclosed for use in the prophylaxis and therapy of hepatitis viral infections. These compounds can be administered alone or in combination with conventional anti-viral agents.
PCT/IB2001/001101 2000-06-23 2001-06-22 The use of synthetic, non-hormonal 21-aminosteroids and thereof WO2001097749A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU74383/01A AU7438301A (en) 2000-06-23 2001-06-22 The use of synthetic, non-hormonal 21-aminosteroids, derivatives, metabolites and precursors thereof in the treatment of viral infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IE20000511 2000-06-23
IES2000/0511 2000-06-23
IES2001/0275 2001-03-21
IE20010275 2001-03-21

Publications (2)

Publication Number Publication Date
WO2001097749A2 WO2001097749A2 (en) 2001-12-27
WO2001097749A3 true WO2001097749A3 (en) 2002-05-23

Family

ID=26320292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001101 WO2001097749A2 (en) 2000-06-23 2001-06-22 The use of synthetic, non-hormonal 21-aminosteroids and thereof

Country Status (2)

Country Link
AU (1) AU7438301A (en)
WO (1) WO2001097749A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508996A (en) * 2002-11-27 2006-03-16 アルタナ　ファルマ　アクチエンゲゼルシャフト PDE4 and PDE3 / 4 inhibitors for use in the treatment of cachexia
DE10311563A1 (en) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Replication assay for the detection of antiviral substances using HTS methods
MD4177C1 (en) * 2011-01-14 2013-02-28 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Method for vaccination against hepatitis B of persons with immunodeficiency
CN107349185B (en) * 2016-07-15 2019-11-26 安徽贝克生物制药有限公司 A kind of emtricitabine tablet and preparation method
CN115137736A (en) * 2022-02-17 2022-10-04 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Medicine for resisting African swine fever virus and screening method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US6194430B1 (en) * 1999-03-31 2001-02-27 The Procter & Gamble Company Viral treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US6194430B1 (en) * 1999-03-31 2001-02-27 The Procter & Gamble Company Viral treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] FLEISHAKER ET AL.: "Biotransformation of tirilazad in human: 2. Effecvt of ketoconazole on tirizalad clearance and oral bioavailability", XP002906907, accession no. STN Database accession no. 8627582 *
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 277, no. 2, May 1996 (1996-05-01), pages 991 - 998 *

Also Published As

Publication number Publication date
WO2001097749A2 (en) 2001-12-27
AU7438301A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
ATE269321T1 (en) MEDICINAL PRODUCTS FOR VIRAL DISEASES
WO2002062290A3 (en) Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
IL143512A (en) Azabicycloalkanes, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments for the prevention or treatment of infection by immunodeficiency virus
IL137922A0 (en) Anti-viral pyrimidine derivatives
CA2413163A1 (en) 3'-prodrugs of 2'-deoxy-.beta.-l-nucleosides
PL344223A1 (en) Compositions for the treatment of hiv and other viral infections
EP1400241A4 (en) Fused cyclic compounds and medicinal use thereof
EE04850B1 (en) Use of pyrimidine derivatives for the preparation of a medicament for the treatment of HIV infection, a compound, a pharmaceutical composition containing it, a process for the preparation of a compound and a composition, and a combination preparation for use in the treatment of HIV infection.
WO2003053344A3 (en) Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
WO2002088124A3 (en) Pyrazolo'1,5-a!pyridine derivatives
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
AU2452288A (en) Nucleoside derivatives useful in treating retroviral infections
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
DE602005011031D1 (en) Phosphoindole als hiv-inhibitoren
WO2005007601A3 (en) Substituted arylthiourea derivatives useful as inhibitors of viral replication
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
EP1256348A4 (en) Remedies for hepatitis c
ATE299709T1 (en) ANTI-VIRAL COMPOSITION CONTAINING A PALMARIA PALMATA EXTRACT
WO2001097749A3 (en) The use of synthetic, non-hormonal 21-aminosteroids and thereof
WO2001025239A3 (en) Oxazinoquinolones useful for the treatment of viral infections
WO2002020509A3 (en) Medicaments against viral infections
CA2195125A1 (en) Difluorostatone antiviral agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)